News
How to Invest in Biotech Stocks
$33,800.That's how much you'd have if you'd invested $10,000 in Alnylam stock just one year ago.Sound enticing? How about $154,980?Continue readingSource: Fool.com
MEDICREA : RACHAT ACTIONS - CONTRAT DE LIQUIDITE - OCTOBRE 2017
PROGRAMME DE RACHAT DE TITRES
Dénomination sociale de l'émetteur :
MEDICREA
Numéro de visa du programme :
Nature des....
VISIOMED GROUP : L'OMS sélectionne VISIOMED GROUP comme fournisseur officiel de solutions de thermométrie / 1ère commande dans le cadre de l'épidémie de peste à Madagascar
Paris, le 8 novembre 2017
VISIOMED GROUP (FR0011067669 – ALVMG), société spécialisée dans l'électronique médicale nouvelle génération, annonce avoir été retenu par l'Organisation Mondiale de....
Here's Why Editas Medicine Collapsed at Market Open Today
Shares of CRISPR gene-editing pioneer Editas Medicine (NASDAQ: EDIT) fell 12.1% shortly after the market opened Wednesday morning. Why? Although the company reported third-quarter 2017 earnings....
Mazor Robotics Enters a New Era
Mazor Robotics (NASDAQ: MZOR), a robotic surgery company focused on spine and brain procedures, reported its third-quarter results on Tuesday, Nov 7th. Revenue more than doubled, margins expanded,....
Why Spectrum Pharmaceuticals Stock Soared in October
Spectrum Pharmaceuticals (NASDAQ: SPPI), a small-cap oncology company, saw its shares gain a whopping 39.2% in October, according to S&P Global Market Intelligence. The drugmaker's stock took....
Here's Why Merck & Co., Inc. Tanked 14% in October
Shares of America's second largest pharmaceutical company, Merck & Co., Inc. (NYSE: MRK) suffered their worst month in years, falling 14% in October, according to data from S&P Global....
Here's What Cost GlaxoSmithKline PLC Nearly $10 Billion in Market Cap in October
Shares of U.K.-based Big Pharma giant GlaxoSmithKline (NYSE: GSK) tumbled during the month of October, according to data from S&P Global Market Intelligence, losing nearly $10 billion in....
BASTIDE : Correctif à l'avis de réunion du 25.10.2017 (Ag 30.11.2017)
BASTIDE LE CONFORT MEDICAL
Société Anonyme au capital de 3.303.261 euros
Siège social : 12, avenue de la Dame, Zone euro 2000
30132 Caissargues
RCS de NIMES N° B 305 635 039
Rectificatif à....
Is the Worst Behind Valeant Pharmaceuticals' Stock?
Valeant Pharmaceuticals' (NYSE: VRX) is knee-deep in a transformation that it hopes will allow it to regain its top-tier status with investors. The company's selling assets and funneling cash flow....
I'm Up 370% on This Under-The-Radar Stock, and I'm Not Selling
Most of your portfolio's returns will be driven by the minority of your stock picks, so a willingness to hold on to your winners long-term can help you beat the market. For example, I'm up more....
Despite FDA OK, Keryx Sinks on Gross-to-Net Surprise
Keryx Pharmaceuticals' (NASDAQ: KERX) Auryxia just won the Food and Drug Administration (FDA) green light for boosting iron levels in non-dialysis chronic kidney disease patients, but shares....
BASTIDE : Avis de convocation à l'Assemblée Générale du 30 novembre 2017
BASTIDE LE CONFORT MEDICAL
Société Anonyme au capital de 3.303.261 euros
Siège social : 12, avenue de la Dame, Zone euro 2000
30132 Caissargues
305 635 039 RCS NIMES
AVIS DE....
3 Unknown, but Amazing, Dividend Stocks
While most income investors focus their time studying large-cap stocks, it's worth remembering that there are scores of small-cap dividend stocks that are worthy of consideration, too. Which....
Why Neos Therapeutics Inc Rose 13.7% In October
Shares of Neos Therapeutics (NASDAQ: NEOS), a small-cap pharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), jumped 13.7% in October according to data from S&P....
Why Inovio Pharmaceuticals Stock Sank in October
According to S&P Global Market Intelligence, shares of the DNA vaccine maker Inovio Pharmaceuticals (NASDAQ: INO) shed 8% of their value last month. On the bright side, this high single-digit....
Here's Why Emergent Biosolutions Dropped as Much as 11.8% Today
Shares of public health threat neutralizer Emergent Biosolutions (NYSE: EBS) fell nearly 12% today for, well, no compelling reason at this time. Sometimes stocks go up, and sometimes they go down.....
Here's Why Invitae Rose as Much as 13.8% Today
Shares of genomics leader Invitae (NYSE: NVTA) rose nearly 14% Tuesday after the company reported third-quarter 2017 earnings Monday afternoon. Investors have become accustomed to eye-popping....
Novo Nordisk A/S Slogs Through the Year
Novo Nordisk (NYSE: NVO) continues to slog through the year, dealing with losing exclusivity on hormone-replacement therapy Vagifem and pricing pressure. The year-over-year comparison for Vagifem....
Why Supernus Pharmaceuticals Inc. Is Having a Rather Non-Super Day
Shares of Supernus Pharmaceuticals (NASDAQ: SUPN), a developer of drugs that target diseases of the central nervous system, plunged as much as 19% during Tuesday's trading session following the....
Is This Why Glaukos Corp. Is Tumbling Today?
Shares of Glaukos (NYSE: GKOS), a medical-device company focused on glaucoma, fell 12% as of 3:25 p.m. EST on Tuesday on heavy volume. However, there wasn't any news that can help to explain the
Here's Why Spark Therapeutics, Inc. Fell 9.3% in October
Shares of Spark Therapeutics, Inc. (NASDAQ: ONCE), a clinical-stage biotech advancing a once-and-done gene therapy approach to treating genetic disorders, have given back some of August's gains.....
The Single Event That Rocketed Arena Pharmaceuticals, Inc. Higher by 10% in October
Shares of Arena Pharmaceuticals (NASDAQ: ARNA), a small-cap biotech company with a focus on a broad array of specialty disease indications, vaulted higher by 10% during the month of October,....
The Big Reason ImmunoGen, Inc. Shed 24% of Its Value in October
Shares of ImmunoGen (NASDAQ: IMGN), a small-cap biotech company focused on the development of antibody-drug conjugates for the treatment of cancer, plunged 24% in October, according to data from....
Here's Why Teligent Stock Was Cut Nearly in Half Today
Shares of specialty generic pharmaceutical manufacturer Teligent (NASDAQ: TLGT) dropped as much as 46% today after investors digested the company's third-quarter 2017 results. Operations appeared....